Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14601423 | 0.86 | GRIA1 (0.45) | KDM4EALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL14601427 | 0.86 | ALDH1A1 (0.44) | KDM4EALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL14601418 | 0.86 | JAK2 (0.42) | KDM4EALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL14601425 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL14601416 | 0.84 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL14601422 | 0.84 | PTGS2 (0.43) | — | |
| SCHEMBL14601424 | 0.82 | HPGD (0.40) | KDM4EALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL14601420 | 0.82 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL14601419 | 0.80 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL14601421 | 0.77 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004713-A1 | Therapeutic benimidazole compounds | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ESR2, ESRRA, ESRRB | KDM4E 2356/4885ALDH1A1 307/4885SMN1; SMN2 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.